AMETEK Inc

NYSE:AME

Earnings Call Analysis

AMETEK's Strong Q1 Performance and Optimistic 2024 Outlook

AMETEK delivered a record-breaking first quarter in 2024, with sales rising 9% to $1.74 billion and earnings per share increasing 10% to $1.64. The company's outstanding performance was driven by exceptional core margin expansion and robust cash flows. Operating margins improved to 25.7%, while EBITDA margins reached 31.2%. Due to these strong results, AMETEK raised its full-year earnings guidance to a range of $6.74 to $6.86 per share, reflecting a 6% to 8% increase from the previous year. The company remains confident in navigating market challenges and expects improved sales growth in the second half of 2024.

Strong First Quarter Performance

AMETEK reported a robust first quarter for 2024, demonstrating strong earnings growth and exceptional operating performance. The company achieved record levels in sales, operating income, and EBITDA, with earnings per share (EPS) increasing by 10% to $1.64, surpassing the guidance range of $1.56 to $1.60. This impressive performance underscores the strength and resilience of AMETEK's growth model.

Operating Segments Insights

The Electronic Instruments Group (EIG) showed a solid start to the year, recording sales of $1.16 billion, up 4% year-over-year. Organic sales growth was positive at 1%, with acquisitions contributing an additional 3 percentage points. Operating income for EIG increased by 14% to $353 million, with operating margins hitting a record 30.5%. On the other hand, the Electromechanical Group (EMG) experienced a strong performance driven by acquisitions, recording sales of $579 million, a 21% increase. However, EMG faced headwinds due to inventory normalization, with organic sales declining by 4%.

Financial Health and Cash Flow

AMETEK's financial health remains robust with a significant free cash flow conversion rate of 123% of net income for the quarter, translating to $383 million. Despite the higher interest expenses due to recent acquisitions, the effective tax rate was slightly reduced to 18.9%. The company maintains a strong balance sheet, ending the quarter with a total debt of $2.9 billion, down from $3.3 billion at the end of 2023.

Acquisition Strategy

AMETEK continues to pursue its acquisition strategy to bolster growth. The Paragon Medical acquisition, completed in December 2023, has already started to contribute positively despite an integration charge of $29 million in the first quarter. This restructuring charge is expected to result in $70 million of benefits over the next two years, reflecting a quick payback period. Paragon added significant value to the EMG, and AMETEK remains confident in leveraging further acquisition opportunities.

Market and Regional Performance

Regionally, AMETEK's performance varied, with the U.S. facing a slight decline in sales by 1% due to tough comparisons. Europe experienced a 2% decline in organic sales, with some strength in the power segment being offset by weaker automation sales. Asia performed better with sales increasing in low single digits, although China remained flat during the quarter.

Outlook and Guidance

Looking ahead, AMETEK maintains a positive outlook for the full year 2024. The company has revised its EPS guidance upward to a range of $6.74 to $6.86, indicating a 6% to 8% increase over the prior year. AMETEK expects overall sales growth in the low double digits on a percentage basis, with low to mid-single-digit organic sales growth. For the second quarter of 2024, the guidance is set for EPS in the range of $1.63 to $1.65, with anticipated total sales growth in the mid to high single digits.

Earnings Call Transcript 2024-Q1

[Operator]

Good day, and thank you for standing by. Welcome to AMETEK's First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Kevin Coleman, Vice President of Investor Relations and Treasurer. Please go ahead.

[Kevin Coleman, executive]

Thank you, Julia. Good morning, and thank you for joining us for AMETEK's First Quarter 2024 Earnings Conference Call. We today are Dave Zapico, Chairman and Chief Executive Officer; and Dalip Puri, Executive Vice President and Chief Financial Officer. During the course of today's call, we will be making forward-looking statements, which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations.

A detailed discussion of the risks and uncertainties that may affect our future results is contained in AMETEK's filings with the SEC. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements. Any references made on this call to 2023 or 2024 results or 2024 guidance will be on an adjusted basis, excluding after-tax acquisition-related intangible amortization and excluding the pretax $29.2 million or $0.10 per diluted share charge in the first quarter for integration costs related to the Paragon Medical acquisition. Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website.

We'll begin today's call with prepared remarks, and then we'll open the call for questions.

I'll now turn the meeting over to Dave.

[David Zapico, executive]

Thank you, Kevin, and good morning, everyone. AMETEK delivered strong results in the first quarter of 2024 with outstanding operating performance leading to double-digit growth in earnings per share. During the quarter, we established records for sales, operating income and EBITDA, and deliver robust core margin expansion and excellent cash flows. Considering our first quarter results and the positive outlook for the back half of the year, we are increasing our earnings guidance for the full year. AMETEK's continued success is a testament to the strength and resiliency of our growth model, the quality of our businesses and the outstanding contributions from all AMETEK colleagues.

Now let me turn to our first quarter results. Sales in the first quarter were $1.74 billion, up 9% over the same period in 2023. Organic sales were down slightly. Acquisitions added 9 points and foreign currency had a small positive impact. Book-to-bill in the quarter was 0.96, and we ended the quarter with a very strong backlog of $3.46 billion near record levels. AMETEK's operating performance at the start of the year was excellent. Operating income in the quarter was a record $446 million, a 10% increase over the first quarter of 2023. Operating margins were 25.7% in the quarter, up 30 basis points from the prior year. Excluding the dilutive impact from acquisitions, core margins were up a very strong 180 basis points versus the prior year. EBITDA in the quarter was also a record at $542 million up 13% over the prior year, with EBITDA margins an impressive 31.2%. This outstanding performance led to earnings of $1.64 per diluted share up 10% versus the first quarter of 2023 and above our guidance range of $1.56 to $1.60.

Now let me provide some additional details at the operating group level. First, the Electronic Instruments Group. The Electronic Instruments Group had a strong start to the year with tremendous operating performance leading to record operating margins and impressive margin expansion. Sales for EIG were $1.16 billion in the quarter, up 4% from the first quarter of last year. Organic sales were up 1% and acquisitions added 3 points. Growth in the quarter remained strongest across our Aerospace & Defense and Materials Analysis businesses.

EIG's operational execution in the first quarter was superb with strong profit and exceptional operating margin expansion. Operating income was $353 million, up 14% versus the prior year, while EIG operating margins were a record 30.5%, up a robust 280 basis points. This level of operating margin speaks to the quality and leadership positions of our highly differentiated businesses.

The Electromechanical Group also delivered solid first quarter operating performance despite the headwinds from inventory normalization impacting some of our EMG businesses. EMG's first quarter sales were a record $579 million, up 21% versus the prior year, driven by contributions from recent acquisitions of Paragon Medical and Bison Engineering. First quarter operating income was $120 million, while core operating income margins were 24.1% in the quarter.

Our first quarter results reflect the unique capabilities of our growth model to successfully manage short-term market headwinds and deliver robust margin expansion, outstanding cash flow and strong double-digit earnings growth. Our businesses remain focused on executing our strategic initiatives and delivering differentiated technology solutions to support our customers' most complex challenges. Our distributed operating structure enables flexibility in responding to market dynamics, while our robust cash flow and balance sheet provide ample support for our acquisition strategy.

This acquisition strategy along with our organic growth initiatives is expanding AMETEK's presence within high-growth markets. These markets include med tech, clean energy, electrification and aerospace and defense and help ensure our diverse portfolio is well positioned to capitalize on these attractive long-term secular growth areas.

We remain committed to investing across our businesses to accelerate new product development and expand our sales and marketing efforts. In 2024, we expect to invest an incremental $100 million in growth initiatives with a sizable portion of this in support of our research, development and engineering efforts. The effectiveness of these investments is reflected in our vitality index which was a strong 25% in the first quarter.

AMETEK's commitment to invest in RD&E and continuously innovate ensures a steady stream of new products that support our customers' critical applications and position us for continued success.

I wanted to take a moment to highlight an example of how the elements of the AMETEK growth model work together to deliver exceptional results. AMETEK Zygo, a global leader in the design and manufacturer of advanced optical metrology systems and ultraprecise optical components was recently awarded AMETEK's Dr. John H. Lux Award, an annual award provided to the AMETEK business that best exemplifies the commitment to continuous improvement and achievements and operational excellence.

As part of its market expansion strategy, Zygo identified an attractive new market segment, virtual and augmented reality applications as a compelling growth opportunity for their advanced optical metrology systems. This led to Zygo's new product development and commercial teams working closely together to advance their technology capabilities and commercialize as a solution to support the highly precise requirements of this application. The success of this work resulted in strong demand and the need for Zygo to meaningfully increase production. Utilizing cross-functional teams and deploying tools like value stream mapping, and Lean Six Sigma, they achieved a remarkable threefold increase in production output, allowing them to meet the growing demand for the metrology solution.

This achievement highlights the synergy between our new product development, global market expansion and operational excellence strategies to help identify, develop and deliver exceptional technology solutions to address an important market need and accelerate growth. Congratulations to the Zygo team for a job well done.

Now switching to our acquisition strategy. The acquisitions we completed in 2023 are integrating nicely into AMETEK. We are leveraging our proven integration capabilities and our global infrastructure to help accelerate their growth, drive operational improvements and deliver strong returns. We are very excited about these acquisitions as they are expanding our market presence in attractive growth markets, including the med tech space through the Paragon Medical acquisition.

Paragon Medical, which we acquired in December, is a leading manufacturer of highly engineered medical components and single-use and consumable surgical instruments. Paragon has an outstanding brand, leading innovation and design capabilities and a strong position serving a number of high-growth market segments. Our integration efforts are focused on supporting and accelerating this growth, while also leveraging AMETEK's infrastructure and operational excellence capabilities to drive efficiency improvements. The integration charge we took in the first quarter will allow us to drive these improvements and better position Paragon for accelerated growth and profitability.

Looking ahead, our acquisition pipeline remains robust, and we are actively working on multiple opportunities. We have the balance sheet and financial capacity to deploy meaningful capital on strategic acquisitions. We look forward to delivering continued value to our shareholders through strategic acquisitions and prudent capital deployment.

Now turning to our outlook for the remainder of the year. We expect the impact of inventory normalization to continue through the first half of the year with improvements in the second half of the year as we indicated on our last earnings call. As a result, for the full year, we continue to expect overall sales to be up low double digits on a percentage basis with low to mid-single-digit organic sales growth. Diluted earnings per share for the year are now expected to be in the range of $6.74 to $6.86, up 6% to 8% compared to last year's results, an increase from the previous guidance range of $6.70 to $6.85. For the second quarter, we anticipate overall sales to be up mid- to high single digits with earnings of $1.63 to $1.65, up 4% to 5% versus the prior year.

In summary, AMETEK delivered a strong first quarter with earnings growth, which exceeded our expectations, driven by exceptional operating performance. We are encouraged by these results and remain confident in our ability to navigate the current environment and benefit from improved sales growth in the back half of 2024. We are confident in the future of AMETEK has our world-class talent and the adaptability of the AMETEK road model will continue to drive long-term sustainable success for our stakeholders.

I will now turn it over to Dalip Puri who will cover some of the financial details of the quarter. Then we'll be glad to take your questions. Dalip?

[Dalip Puri, executive]

Thank you, Dave, and good morning, everyone. As Dave highlighted, AMETEK had a very strong first quarter with record level sales and exceptional operating performance, highlighted by strong core margin expansion and free cash flow conversion.

Now let me provide some additional financial highlights for the first quarter. First quarter general and administrative expenses were $26.4 million or 1.5% of sales, in line with last year's first quarter. For fiscal year 2024, general and administrative expenses are expected to be approximately 1.4% of sales.

First quarter interest expense was $35 million, up $15 million from the prior year first quarter due to higher debt balances outstanding following the December 2023 acquisition of Paragon Medical. Other operating expenses were down $5 million primarily due to higher interest income and higher pension income compared to the prior year's first quarter. The effective tax rate was 18.9%, down from 19.5% in the first quarter of 2023. For 2024, we continue to anticipate our effective tax rate to be between 19% and 20%.

As we have stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively from this full-year estimated rate. Capital expenditures in the first quarter were $28 million, and we continue to expect capital expenditures to be approximately $160 million for the full year or about 2% of sales. Depreciation and amortization expense in the quarter was $98 million. In 2024, we expect depreciation and amortization to be approximately $400 million, including after-tax acquisition-related intangible amortization of approximately $190 million or $0.82 per diluted share.

Operating working capital in the first quarter was 18.7% of sales. Operating cash flow was $410 million, up 6% versus the first quarter of 2023, while free cash flow was $383 million, up 4% over the prior year. For the quarter, free cash flow conversion was a strong 123% of net income. For the remainder of 2024, we continue to expect strong free cash flow conversion in the range of 110% and 120% of net income. Total debt at March 31 was $2.9 billion, down from $3.3 billion at the end of 2023.

Offsetting this debt, it's cash and cash equivalents of $374 million. At the end of the first quarter, our gross debt-to-EBITDA ratio was 1.3x, and our net debt-to-EBITDA ratio was 1.2x. We continue to have excellent financial capacity and flexibility with approximately $1.8 billion of cash and available credit facilities to support our growth initiatives and our active acquisition pipeline.

While acquisitions remain our #1 priority for use of our free cash flow, we also seek to opportunistically repurchase our shares and provide our shareholders with a consistently increasing dividend. And in February, we announced a 12% increase in our quarterly cash dividend to $0.28 per share, our fifth consecutive year of 10% plus annual increases.

In summary, our businesses delivered strong results to start the year with outstanding operating performance, leading to robust core margin expansion and excellent free cash flow.

Kevin?

[Kevin Coleman, executive]

Thank you, Dalip. Julie, can we please open the lines for questions?

[Operator]

[Operator Instructions] Our first question comes from the line of Deane Dray of RBC.

[Deane Dray, analyst]

Can we start off with the usual kind of tour of the end markets and geographies and maybe finish up with the -- just kind of the destocking comments. It just continues to be drawn out, and we're seeing it in all kinds of pockets. So it's not AMETEK specific in any way. But just kind of what's your refresh feel on that as well?

[David Zapico, executive]

Sure, sure. Glad to do that all, Deane. I'll start with the walk around the company, and I'll start with our Process business. Overall sales for our Process businesses were roughly flat versus last year and in line with our expectations. Growth remains solid across our energy and semiconductor businesses, and we're really well positioned there to benefit from the sizable project and investment activity within these markets. For the full year, we continue to expect sales for our Process businesses to be up low single digits.

Next, I'll switch to Aerospace & Defense, and our A&D businesses, had a strong start to the year with approximately 10% organic growth in the quarter. Growth was very solid across both our commercial, aerospace and defense segments and for all of 2024, we continue to expect organic sales for our A&D businesses to be up high single digits on a percentage basis with similar growth across both our commercial aerospace and defense businesses.

Next, I'll move to Power. Our Power businesses were up low double digits in the first quarter with contributions from the acquisitions of UEI and Amplifier Research being offset by a low single-digit decrease in organic sales. These recent acquisitions along with the acquisition of RTDS in 2022, expanded our presence within a number of highly attractive market segments, which are expected to benefit from a strong investment cycle, including the expansion of renewable energy and the power grid infrastructure. And for the Power segment, we continue to expect low to mid-single-digit organic sales growth for 2024.

And finally, going to the Automation & Engineered Solutions market segment, overall sales for A&ES were up 20% on a percentage basis in the quarter -- were up mid-20s in the quarter with contributions from the acquisitions of Paragon Medical and Bison Engineering being offset by a high single-digit decrease in organic sales. As we expected, the impact from normalization of inventory levels across our OEM customer base continued in the first quarter, and we expect to see a return to growth in the second half of the year consistent with what we had indicated last quarter.

And then finally, as a result, we continue to expect organic sales for our automation businesses to be up low single digits stronger growth in the back half of the year. So that's the walk around the company. And I think you also asked for what's going on in the various geographies. So get to that too, Deane.

The U.S. was down 1% against a pretty difficult comparison, and our strongest growth was in our aerospace and defense businesses. Moving to Europe, we were down 2%, so minus 2% organic with notable growth in parts of our process and parts of our Power businesses offset by weakness in automation. And in Asia, we were up low single digits with strength across our Process businesses. So we had a very good performance in Asia. And digging down into that a little further, China was flat in the quarter, we saw the growth in our parts of our process businesses. So up low single digits in Asia and China was flat.

[Deane Dray, analyst]

It's all really help. Go ahead.

[David Zapico, executive]

Yes. You asked about the destock, Deane. Yes, I think that it's playing out as we had talked about last quarter. I think the destock will continue into the second quarter, but in the second half of the year, we expect that to turn around. So we're watching that closely and it's really kind of playing out as we thought. I mean, the destock was probably a bit more than we thought it was going to be in Q1, but that may be positive for later in the year because we think second half of the year is just positive.

[Deane Dray, analyst]

Great. And just a quick follow-up on the growth investments. We know this is your playbook. Is there anything unique in terms of how you're deploying that capital? I mean, typically, it's salespeople, is a component, but any other kind of wrinkles here you could share?

[David Zapico, executive]

Yes. It's salespeople with the largest chunk of it is in the engineering, research, development and engineering. And we have a full slate of projects, we have excellent opportunities longer term and we're getting after them. So I'm very positive on what's happening in our new product development programs.

[Operator]

Our next question comes from the line of Jeffrey Sprague of Vertical Research Partners.

[Jeffrey Sprague, analyst]

Can you just address a little bit more Paragon itself, how it's performing and the charge that you took I don't recall a large charge like this on prior deals, maybe there are smaller ones that you just absorbed but didn't break out, but kind of the nature of what you're trying to accomplish? And is this kind of a onetime deal in this quarter as you kind of bed down the asset?

[David Zapico, executive]

Yes, that's a great question, Jeff. And it's kind of what you said. I mean we typically absorb the smaller acquisitions as we proceed through the years and quarters. And the last time we did something like this, when we bought, I believe, Zygo, is a bigger acquisition. And because of the size of the acquisition and because of the opportunities that we see, we wanted to take that integration charge because there are tremendous, tremendous opportunities to improve the business. So it's a onetime nature. It's for larger deals as you know, Paragon was largest acquisition that we have done.

We spent about $1.9 billion. So as we dug into it, as we work with our management team, we got really comfortable with this plan. Quite honestly, there's more opportunities than we thought. We have a good team of both AMETEK and Paragon leaders that are really getting after it now. So I feel really good about the business.

The integration is being integrated into AMETEK well, it's very positive around the future. And I think this restructuring is largely going to happen over the next couple of years, and we really see as a less than 2-year payback on it. So excellent payback. And we started on that, and we're really positive of what we're doing, and I feel positive about the deal.

[Jeffrey Sprague, analyst]

Great. And then maybe just switching gears, and I'm sorry if I missed it, I was on a little bit late, but can we just decompose revenue growth in the quarter for the segments, some color on what the organic performance was at the segment level? And if you have any color on price or other elements of revenue. I'm curious...

[David Zapico, executive]

Yes, if you look at -- our overall sales were up 9%. That's because both groups. And go the organic growth was just down modestly, about 0.5 point. EIG overall sales were plus 4. The organic growth in EIG was plus 1%. EMG overall sales were plus 21% and the organic sales at EMG were minus 4. So you had that defines the group dynamics for revenue.

[Jeffrey Sprague, analyst]

And maybe just 1 last 1 back to this kind of destock question. Just to comment that it was more in Q1 than expected, and I know it's kind of hard to know what your customers are going to do. But just your confidence level that it actually is, in fact, destock and like you have visibility on sell-through being better on the other side? Maybe just kind of address that, if you could?

[David Zapico, executive]

Yes, yes. The first point is when you look at AMETEK's first half, second half, we typically have 48% of our revenue and profits in the first half of the year, and 52% of our revenue and profits in the second half of the year, and that's exactly what we have this year. So our second half of the year is not back-end loaded. So we feel good about that.

Another point that you may not see it really appears our orders have stabilized. Specifically, when I look at Q4 '23 to Q3 '23, and then I look at the next quarter, Q1 '24 the last quarter compared to Q2 '23. So the last 2 quarters sequentially, with all the acquired backlog removed. So really looking at a true run rate sequentially. We've seen low single-digit growth in orders in both Q4 '23 and Q1 '24. So it feels like we've bottomed and we're starting to see some modest improvements. At the same time, in Q1 '23, we had an extremely good quarter. So we have a difficult comp that we're battling.

And finally, and perhaps most importantly, we've had customer commentary that continues to communicate to us in the second half of the year that destocking phase will come to an end, and we should return to a positive book-to-bill.

So in terms of the economic environment, we're not -- we're watching it closely, but for the balance of the year, we're just assuming modest economic growth, not any kind of economic acceleration and at the same time, not a recessionary environment. And we expect that we'll grow sales modestly each quarter and the comparables get easier in the second half of the year. And as I said, this 48%, 52% split, H1 to H2 is very much aligned with our historical averages.

[Jeffrey Sprague, analyst]

And I'm sorry, did you have a comment on price? I missed it, and I'll see the floor.

[David Zapico, executive]

That's a good question, Jeff. Pricing was continued to more than offset inflation. Pricing was approximately 4% in the quarter and inflation was about 3%. The results speak to the highly differentiated nature of the AMETEK product portfolio and our leadership position in these niche markets around the globe. And for the full year, we do expect their pricing to come in a bit and inflation to come in a bit, but we expect to maintain a positive spread between them.

[Operator]

Our next question comes from the line of Brett Linzey of Mizuho.

[Unknown Analyst]

This is [indiscernible] for Brett Linzey. So as we look at a more potentially more aggressive tariff regime, can you just talk about how nimble your supply chain configuration is and then your ability to flex around different regions if needed?

[David Zapico, executive]

Yes, it's a great question. I mean we look at tariffs, and that became a bigger issue back in the 2017 time frame. And in the quarter, we had a minimal impact from tariffs and they were completely offset for price. And to give you an idea across the whole company, tariffs are only going to cost us about $0.01, a $3 million or $4 million. And what happened there is we've aggressively rebalanced our supply chain. It's largely done. So we're not overexposed to any region of the globe. And we have a strategy where from the U.S., we're largely sourcing from Mexico and other regions of the Americas and in Europe. We do a lot of sourcing from to Czech Republic and Serbia. And in Asia, we do a lot of sourcing from Malaysia.

So we've got a nice balance around the world. So I think the hard work that we did over the past few years are really rebalancing our supply chain. We're essentially finished with it, just very small bit of work that continues. And we're very well positioned to be able to deal with an increasing tariff regime, specifically with China, in particular, we don't have a real risk there. We do excellent business in China. It's a China kind of strategy is about 9% of our sales. And largely, we source what we sell in China. So we're in a pretty good position in terms of tariffs.

[Unknown Analyst]

Perfect. And then if you can just provide some color on the tempo or monthly cadence of trends in the quarter and then looking into April?

[David Zapico, executive]

Yes. I mean it was a pretty typical quarter. March was the strongest -- excuse me, March was the strongest quarter. Wait a minute. Okay, yes, pretty typical quarter, with March being the strongest on both orders and sales. So it's -- sales were the highest of the quarter in March and then in April, we're right on plan. So we feel good about the guidance. And it's pretty -- as I said, it's bouncing around there. But we're not seeing any incremental weakness at this point.

[Operator]

Our next question comes from the line of Scott Graham of Seaport Research Partners.

[Scott Graham, analyst]

Really, maybe the first question is about the M&A environment. EBITDAs do seem to have firmed up even though this first quarter, I think, most would say industrial land has been a little uneven. Nevertheless, when EBITDA is firm up, that's kind of when I think the AMETEK does a lot of striking. And I'm just wondering, are we looking at a year this year that could mirror last year? I mean what is like the really near-term pipeline look like, Dave?

[David Zapico, executive]

Yes, it's very, very difficult to predict the very near term. But Scott, the pipeline remains very strong, and we're actively looking at a number of high-quality deals across a broad set of markets. So we have $1.8 billion of existing cash and credit facilities post Paragon. We have a balance sheet that would support -- if the deals meet our criteria, we could do over $4 billion of deals this year, and that would only take our leverage up to about 2.5x. So we're really in an excellent position. And it's not a balance sheet issue. It's not a cash flow issue.

We're performing extremely well. it comes down to finding the right businesses, and we have a good pipeline right now, a very good pipeline. And we really have the opportunity, as you said, we typically have this opportunity to differentiate our performance with the M&A element of our growth strategy with this strong balance sheet and with the strong cash flow position. So in this market is a bit choppy. Our combination of OpEx and M&A and this proven acquisition strategy, I'm really looking to differentiate our performance with our M&A and our OpEx during the next couple of quarters.

[Scott Graham, analyst]

You answered one of Jeff's questions earlier, saying you're expecting sales to be up modestly each quarter. Were you referring to organic for the next 3 quarters?

[David Zapico, executive]

Yes. This is sequential, Scott.

[Scott Graham, analyst]

Okay. So sequentially, you're expecting sales dollar to be up.

[David Zapico, executive]

Q1 will be a bit higher than Q2, Q3 a bit higher than Q2 and Q4 will be a bit higher than Q3.

[Scott Graham, analyst]

Okay. And the last one is just sort of back on the orders. I know you do have a pretty significant comp that you're up against when you stack them. What were orders in the quarter in dollars and in organic?

[David Zapico, executive]

Yes. The orders were -- orders were minus 8 and organic orders were minus 10. And again, we had a tough comp, and I went through the process of they sequentially grew low single digits the last couple of quarters. When you take out the comp, I think in Q1 of '23, we had exceptional orders from some project business and EIG in particular. So when you take that out and you look at what's going on sequentially, we get more comfortable.

[Scott Graham, analyst]

Yes. No, I get it, '22 and '21 were also exceptional organic periods for you.

[David Zapico, executive]

Yes.

[Operator]

Our next question comes from the line of Andrew Obin of Bank of America.

[Andrew Obin, analyst]

Just a question, how to think about the Paragon Medical integration costs. So what's the payback on this restructuring that's now -- because I assume it's extra. So what's the payback on this restructuring that's embedded in '24 guide? And how much of it should I add to '25?

[David Zapico, executive]

Yes. Well, in '24, we had told you in prior meetings that Paragon is going to contribute $0.08 to $0.10 to AMETEK's EPS, and that still holds. When I look at that $22 million charge, we said the payback is going to be less than 2 years, and at run rate, so it will take us a couple of years to get there. But the run rate, we have $70 million of benefit. So we spent approximately $29 million. We're going to get approximately $70 million of benefits. The payback is less than 2 years. So that really tells you what a great return it has, and it's just -- there wasn't a lot of focus, and we can run things really efficiently. And I'm just excited that the management team sees it that way, too, and we're really going to make Paragon an exceptional business from an operating perspective.

Regarding 2025, I think we've come out and said that we should see a substantial increase in operating earnings related to Paragon in 2025. But I'm not willing to quantify what's going to happen in 2025. We're much too far away to do that. But again, the metrics I'd point you to are we spent $29 million. We'll see $70 million in benefit at max run rate. And the payback for the project is a little less than 2 years. So we feel really good about it, good payback for our shareholders.

[Andrew Obin, analyst]

Sorry, I'd probably -- and I'd probably take it offline, but just to make sure, so I thought the Paragon restructuring was extra because you saw incremental opportunities. So you were saying that I should have -- that, that was embedded all along but was not in the guide. I'm sorry...

[David Zapico, executive]

I just think that it's a larger deal, and we saw a lot of opportunities over -- it will take us a few years to do it so we put it forward.

[Andrew Obin, analyst]

Okay. I'll take it offline because I'm not sure if I -- so I should have had it in my numbers or this $0.10 is extra on top of view we're thinking, just confirming that, I apologize. And I'm happy to take it offline with Kevin, I apologize.

[David Zapico, executive]

Yes. I don't know what you have in your numbers, Andrew. I don't really look at them, but I can tell you that we're expecting to get $0.08 to $0.10 of benefit from Paragon and this restructuring doesn't change that.

[Andrew Obin, analyst]

Got you. That makes sense. And then just on revenue and you did give very good color was basically the destock what drove -- I guess you were expecting I think you guided for low double-digit revenue in the first quarter, a little bit below. So it's just you said it's destock pulled forward, correct?

[David Zapico, executive]

Yes.

[Operator]

Our next question comes from the line of Christopher Glynn of Oppenheimer & Co. Inc.

[Christopher Glynn, analyst]

Dave, I was curious just to go into the top a little bit of the long-term multiyear kind of secular trends where you see an impact. It occurs to me maybe the Power business could be on your leading edge with energy transition and electrification. But curious your comments in general on the kind of secular trends, and in particular, what you're seeing as kind of street level evidence on reshoring type trend.

[David Zapico, executive]

Yes. I think the -- when I think about the long-term secular growth drivers, and we talked about a little -- a few of them in my talk, but a lot of project activity around the semiconductor market, and that's finally we're moving closer and closer to the point where that's going to start turning into business for us in the West. There's a lot of project work on semiconductors.

The Power market, as you said, and there are really two drivers there, the driver for renewables, energy but also the driver for investments in the power grid. So our RTDS business or power instrumentation business are really levered to those. So that's starting to happen as work its way through.

When I think about the Aerospace & Defense business. Again, we had a great quarter again, and that's continuing. And I think both Airbus and Boeing have a 9-year backlog for the commercial market looks good. Our defense -- we're in the right position in defense. We had another good quarter in defense. So I think about those kind of markets and those trends, I feel good about the future, and a lot of fiscal stimulus in the U.S., which has not been there in the past. And -- but it takes time to work through the system. So we think longer term, I think we're in the right places to do well.

[Operator]

Our next question comes from the line of Joe Giordano of T.D. Cowen.

[Unknown Analyst]

This is Dan on for Joe. Sorry, I know destocking and bottoming of orders within automation has been discussed a few times. So just a quick follow-up. This is obviously something a lot of companies have been struggling with in the past few quarters. But some have also been talking about changing their internal processes to gain more visibility of end market and end users. Is there anything that you guys have done potentially more frequent conversations or reaching out to like end market users to understand a bit better their demand going forward? Anything you've changed recently?

[David Zapico, executive]

I can't point to anything to change. I mean if you go back and you follow us, we kind of call exactly what happened. We talked about the first half of the year of sales outpacing orders. So that means you'd have a slightly below 1 book-to-bill.

And we talked about the destock in the first half, and we thought it would turn positive in the second half. We did that before this quarter. I think we have a pretty robust communication system with our field, but there's always opportunities to get better and we work on those and continuously improve our businesses. But I feel like the information that we got from the field is pretty accurate, and we're on top of it. So -- but there's always room to improve, and we're always looking at ways to improve.

[Operator]

Our next question comes from the line of Nigel Coe of Wolfe Research.

[Nigel Coe, analyst]

David, I just want to come back to the order math. I think you said down 8% and then down 10% organic.

[David Zapico, executive]

Right.

[Nigel Coe, analyst]

We've got about 9 points of contribution from Paragon in our numbers. So just wondering what am I missing, I've expected that there would be significant contribution from Paragon in the order numbers. So just help me out with that math, please.

[David Zapico, executive]

Yes. We had 9% acquisition growth, and Paragon is in the acquisition is not the organic. So the Paragon sales orders -- sales, excuse me. Yes.

[Nigel Coe, analyst]

Okay. But then the orders, 8% organic to, that makes sense, reported downtimes in organic. Was there no material impact from Paragon there?

[David Zapico, executive]

Yes. With Paragon, we had obviously, the large -- look the backlog as orders in Q4. And then in Q1, there's a timing issue because Paragon has gone through the same destock that the EMG business is. So there's a bit of a destock there. That impacts the orders.

So the medical market, it's in both our EMG business and Paragon, we're seeing the same kind of destock in the EMG businesses. If we look at the medical procedures, they're all growing at mid- to high single digits, but the medical device OEMs are destocking their inventory, correcting their inventories. It's kind of a widely communicated piece of information, and we monitor the procedures, and they're growing. So this destock we think is going to run a space through the first half of the year.

[Nigel Coe, analyst]

Okay. Does that impact the full year forecast? I think we've got close to $5 million of sales Paragon, does that destock impact that outlook. But also... I do.

[David Zapico, executive]

Go ahead.

[Nigel Coe, analyst]

No, no. Please go ahead, Dave.

[David Zapico, executive]

Yes. I think for the year, when we bought Paragon, it was a little less than $500 million. And the first year, we talked about the mid-single-digit growth. So that's still exactly what we have in our model. So we think that we get out of this year, and we think it will be a double-digit grower over the next couple of years, but the Paragon model from the viewpoint of what we had going into the year and what it is now is pretty much identical.

[Nigel Coe, analyst]

Okay. And then just, sorry, a follow-up on the $29 million. Is that all restructuring? Or is there some inventory and accounting break down?

[David Zapico, executive]

Yes. I'd say the vast majority of it was restructuring, and there was a small part of it that were other integration costs. But the vast majority...

[Nigel Coe, analyst]

And does some of that come into 2Q as well? Do we think about that into 2Q?

[David Zapico, executive]

Yes. We started the effort in Q1 and as I said, we pulled forward all the benefits that we had. And I think the restructuring is -- was done in Q1. So I don't think we're going to have another restructuring charge in Q2, if that's what you're asking.

It's a one-off charge. It's a one-off charge. The Zygo business, we had a big acquisition. We did a similar thing when we got comfortable with what we could do. And we may have another charge with Paragon down the road if we think there's other ways to improve it. But right now, this is a onetime charge to dramatically improve the operating capability of that business and the returns that I communicated to you are very positive.

[Operator]

I am showing no further questions at this time. I would now like to turn it back to Kevin Coleman, Vice President of Investor Relations and Treasurer, for closing remarks.

[Kevin Coleman, executive]

Thank you. Thanks, everyone, for joining our call today. And as a reminder, a replay of today's webcast may be accessed in the Investors section of ametek.com. Have a great day.

[Operator]

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.